A new clinical platform launched today replaces one-time DNA reports with continuously updated dashboards that integrate genomic data, biomarkers, and lifestyle information to help practitioners move from genetic interpretation to concrete patient care decisions. EndoDNA, a precision health intelligence company, unveiled BIOS (Biomedical Reasoning and Adaptive Inference Network), a patented decision-support system designed specifically for licensed healthcare practitioners working in functional, integrative, regenerative, and longevity medicine.

The core problem BIOS solves is deceptively simple but profound: clinicians today have access to more biological data than ever before, yet lack practical tools to act on it. Traditional genetic testing platforms deliver a static report once, then the information sits unused. BIOS changes that equation by creating a living, evolving view of each patient's biology that updates as new data arrives.

"For years, clinicians have had access to more biological data than ever before, but very few tools to help them actually apply it. Most genetic platforms stop at information. BIOS was built to answer the question clinicians are really asking: 'Now what?' It transforms complex biology into structured clinical insight that evolves alongside the patient; helping providers move from interpretation to action with greater clarity and consistency," said Len May, Founder and CEO of EndoDNA.

Len May, Founder and CEO of EndoDNA

What Makes BIOS Different From Consumer DNA Tests?

Most consumer DNA platforms focus on isolated genetic variants, often called SNPs (single-nucleotide polymorphisms), treating each one as a separate data point. BIOS takes a fundamentally different approach by organizing genetic information around interconnected biological pathways rather than individual variants. This pathway-based architecture reflects how the human body actually works, where genes don't operate in isolation but interact within larger systems.

The platform analyzes approximately 1 million validated genetic variants across 21 different pathway systems, with 214 pathways actively curated for real-time clinical decision support. These pathways include hormone metabolism and metabolic signaling, inflammation and stress response, and neurotransmitter regulation and cognitive function. Rather than asking "What does this one gene variant mean?" BIOS asks "How does this variant fit into the patient's broader biological picture?"

How Does BIOS Build a Complete Picture of Patient Biology?

BIOS uses four interconnected "memory networks" that work together to create increasingly personalized recommendations over time. Understanding these layers reveals why the platform can adapt and improve as it learns more about each patient:

• World Network: Integrates population-level genomic evidence from biobanks, clinical pharmacogenetics databases (CPIC), and pharmacogenomics knowledge bases (PharmGKB) to ground recommendations in large-scale research data.
• Experience Network: Draws on aggregated case histories from practitioners using the platform to surface patterns about what has worked for similar patients in real-world practice.
• Opinion Network: Captures individual practitioner notes and clinical overrides, allowing doctors to refine and personalize recommendations based on their own expertise and patient-specific context.
• Observation Network: Tracks patient-reported outcomes and biomarker trends over time, creating a longitudinal record that shows whether interventions are actually working.

This multi-layered approach means that BIOS doesn't just interpret a patient's genes once; it continuously refines its understanding as new clinical data arrives. A practitioner might order specialized reports on female regenerative health, nutrigenomics and metabolic pathways, or endocannabinoid system function, and the platform integrates all of that information into a single HIPAA-compliant dashboard.

What Clinical Tools Does BIOS Provide to Practitioners?

Through a single interface, licensed practitioners can order DNA tests, generate unlimited specialized reports from existing genetic data, integrate biomarker and lab results, analyze how medications might interact with a patient's genetics, and search patient genomic data using natural language queries. The platform supports report categories including female and male regenerative health, cognitive and neurological health, nutrigenomics and metabolic pathway analysis, endocannabinoid system panels, and hormone optimization and longevity pathways.

EndoDNA has already served more than 10,000 patients across nine countries through CAP/CLIA-accredited laboratory partners, using Illumina next-generation sequencing to achieve a 99.6% genotyping accuracy rate. The company holds more than 10 issued and pending patents, including the only patented methodology for genotyping the endocannabinoid system and a patented machine-learning approach for predicting treatment efficacy from genetic and biometric data.

Why Does the Shift From Static Reports to Adaptive Dashboards Matter?

The precision medicine field has long struggled with a fundamental gap: genetic research identifies thousands of disease-associated variants, but connecting those variants to actionable clinical decisions remains difficult. A separate line of research using CRISPR screening technology highlights why this problem is so significant. Genome-wide association studies (GWAS) have linked thousands of genetic variants to disease risk, yet most remain disconnected from drug-relevant biology because researchers struggle to determine which variants are actually causal and how they exert their effects.

"A key problem in the age of GWAS, when we are collecting thousands of genetic variants and disease associations, is knowing which variants are most important to focus on for a particular disease. GWAS is fantastic at finding genetic associations but, as we've all learnt, correlation does not equal causation," explained Neville Sanjana, Professor of Biology and Neuroscience at New York University and Core Faculty Member at the New York Genome Center.

Neville Sanjana, Professor of Biology and Neuroscience at New York University

BIOS addresses this challenge by providing practitioners with a structured way to interpret complex genomic data in the context of each patient's unique biology. Rather than leaving clinicians to manually piece together information from multiple sources, the platform automates the integration and reasoning process, allowing practitioners to focus on clinical judgment and patient care rather than data interpretation.

The launch of BIOS represents a shift in how precision medicine platforms are designed. Instead of treating genetic data as a one-time snapshot, the platform acknowledges that patient biology is dynamic and that clinical decision-making improves when practitioners have access to continuously updated, integrated information. For practitioners working in functional and integrative medicine, this approach offers a scalable way to deliver truly personalized care without requiring them to become expert bioinformaticians.